drugset / Trial / NCT05419505

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505

Phase 2 Completed 91 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium histolyticum-aaes \[CCH-aaes\]).

Timeline

Start
2022-06-15
Primary completion
2023-01-03
Completion
2023-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic Subcutaneous